Welcome to Alexion's aHUS Portal.
aHUS is a rare disorder caused by uncontrolled complement activity, leading to progressive and life threatening complications. 1-3

Patients with aHUS experiencing a TMA manifestation can develop organ damage rapidly. 2,4
If you want to learn more about
aHUS disorder please click here
TMA:thrombotic microangiopathy
aHUS: atypical hemolytic uremic syndrome
ALGORITHM TO RAPIDLY DIFFERENTIATE DIC, TTP AND AHUS IN THE ICU5
How to rapidly differentiate
DIC, TTP and aHUS in ICU?
Vincent et al. (Critical Care 2018) proposed a concise algorithm based on existing guidance and their own discussions which should assist in distinguishing between these entities5
Click Here
TMA:thrombotic microangiopathy
DIC: disseminated intravascular coagulation; TTP: thrombotic thrombocytopenic purpura
ALEXION & aHUS DISORDER
If you want to learn more about patient results, please click here
Download PDF
Soliris - Summary of Local
Product Information
Soliris is indicated in adults and children for treatment of atypical haemolyric uremic syndrome (aHUS).
ALEXION'S COMMITMENT TO CHANGING aHUS PATIENTS' LIVES
If you want to learn more about ULTOMIRIS (ravulizumab), please click here
Download PDF
Ultomiris - Summary of Local
Product Information

ULTOMIRIS® is not yet reimbursed in Belgium

This medicinal product is subject to additional monitoring. HCPs are asked to report any suspected adverse reactions. This will allow quick identification of new safety information
Time for a coffee?* Time for a Survey!
*The coffee is on you, the survey is on us

Take a 5-minute survey to help us deepen our knowledge and provide better solutions.
Take the Survey